Nutex Health Inc.·4

Mar 11, 4:35 PM ET

Bates Jon Christian 4

Research Summary

AI-generated summary

Updated

Nutex Health (NUTX) CFO Jon Bates Converts RSUs to 2,667 Shares

What Happened

  • Jon Christian Bates, Chief Financial Officer of Nutex Health (NUTX), converted 2,667 restricted stock units (RSUs) into 2,667 common shares on March 10, 2026 at a reported price of $0.00 (no cash paid).
  • On March 11, 2026 he was granted 1,694 additional RSUs (reported as a derivative award). Those RSUs were reported on the Form 4 and will vest in three equal installments on March 1, 2027, March 1, 2028 and March 1, 2029. These transactions are awards/conversions of equity compensation, not open-market purchases or sales.

Key Details

  • Transaction dates and prices:
    • Mar 10, 2026: exercised/converted derivative (M) — 2,667 shares acquired at $0.00 (conversion of RSUs).
    • Mar 11, 2026: derivative report (M) for grant of 1,694 RSUs (see vesting schedule below); no cash consideration.
  • Total reported cash value: $0 for the conversion (shares issued on conversion of RSUs); grant value not shown on Form 4.
  • Shares owned after transaction: not disclosed in the provided filing excerpt (see the full Form 4 for total beneficial ownership).
  • Footnotes of note:
    • F1: RSUs convert one-for-one into common stock.
    • F2: The 1,694 RSUs granted on March 11, 2026 vest in three equal annual installments (Mar 1, 2027; Mar 1, 2028; Mar 1, 2029).
  • Filing timeliness: Form 4 was filed on Mar 11, 2026 for transactions on Mar 10–11, 2026; this appears to be timely (not marked late).

Context

  • RSU conversions and grants are compensation events. The Mar 10 conversion reflects previously granted RSUs becoming common shares (no cash changed hands), while the Mar 11 entry documents a new RSU award that vests over time.
  • These actions are not open-market purchases or sales and do not necessarily signal a personal buy/sell decision; they reflect company compensation and vesting mechanics.